SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma’s arm inks MoU with overseas technology provider

04 Mar 2023 Evaluate

Orchid Pharma’s wholly owned subsidiary -- Orchid Bio-Pharma has entered into a Memorandum of Understanding (MoU) with an overseas technology provider for in-licensing 7ACA technology.

Earlier, Orchid Bio-Pharma had received approval to manufacture the product ‘7 ACA’ with a committed capacity of 1000 Metric Tonne Per Annum. This approval will help the company in backward integration, reduce dependency on sourcing from China and aid in improving margins.

Orchid Pharma, established as an export-oriented unit (EOU), is a vertically integrated company spanning the entire pharmaceutical value chain from discovery to delivery with established credentials in research, manufacturing and marketing.

Orchid Pharma Share Price

572.95 8.85 (1.57%)
17-Apr-2026 10:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1690.00
Dr. Reddys Lab 1221.80
Cipla 1235.50
Zydus Lifesciences 941.35
Lupin 2322.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×